Cutia Therapeutics (2487) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Cutia Therapeutics stock HK$0.89, price HK$0.68, upside +31.4%, quality 41 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Cutia Therapeutics
2487 · HKCheap enough by our rule, but weak company and falling price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
41‑month range HK$0.6700 – HK$30.90 · fair‑value band HK$0.6703 – HK$1.12 · the HK$0.6800 price screens below the HK$0.8938 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Every Wednesday you see whether Cutia Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People's Republic of China and Hong Kong.
Show moreShow less
It focuses on the dermatology treatment and care therapeutic areas, including scalp diseases and care, skin diseases and care, topical anesthesia and localized adipose accumulation management medication.
The company provides CU-40102, a topical finasteride spray for androgenetic alopecia treatment; and CU-10201, a topical 4% minocycline foam for acne vulgaris treatment.
It is also involved in the development of CU-20401, a recombinant mutant collagenase, currently under Phase II clinical trial for submental adipose accumulation (submental fat); CU-40101, a topical small molecule thyroid hormone receptor agonist liniment, currently completed Phase I clinical trial for the treatment of androgenetic alopecia; and CU-30101, a localized topical lidocaine and tetracaine compound topical anesthesia cream, completed Phase III clinical trial for surface dermatologic operations.
In addition, the company provides CATAME, a technology platform that enables the development of a wide range of product dosage forms and the relevant formulation technology.
Further, it offers product pipeline of creams, sprays, ointments, aerosol foams and other dosage forms through the CATAME platform. The company was incorporated in 2019 and is headquartered in Shanghai, China.
Stock analysis
Cutia Therapeutics (2487) currently trades at HK$0.6800, while our estimate is HK$0.8938, so the stock looks roughly fairly valued today (gap 23.9%).
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: HK$0.6703 (bear) to HK$1.12 (bull), the price of HK$0.6800 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Cutia Therapeutics reported revenue of 336M CNY in FY2025 versus 2.0M CNY in FY2021, a compound +258.4%/yr. Reported net income was −340M CNY in FY2025.
Key figures
Market cap HK$253M (≈ $32.3M) Micro · P/S ratio 0.81 · Net margin −101% · Return on equity −38.3% · Return on assets (EBIT) −24.3% (5-year average) · Operating margin −235% · Revenue (TTM) 333M CNY · Revenue growth (YoY) −5.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).
What moves the price
The share trades about 91% below its 52-week high and 1% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 31%, 2487 screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Watch 2487, get fair value alerts →
Compare Cutia Therapeutics with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Quality Score by industry
- Return on equity by industry
- Stock screener with 62 metrics
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $955.47 | $1,275 | +33% | vs 2487 |
| Vertex Pharmaceuticals Incorporated VRTX | $538.60 | $592.46 | +10% | vs 2487 |
| Samsung Biologics Co 207940 | 1,411,000 KRW | 1,552,100 KRW | +10% | vs 2487 |
| Genmab A/S GMAB | kr 3,448 | kr 3,793 | +10% | vs 2487 |
| argenx SE ARGX | $960.04 | $908.40 | −5% | vs 2487 |
| CSL Limited CSL | A$202.52 | A$185.51 | −8% | vs 2487 |
| Moderna, Inc MRNA | $223.37 | $139.99 | −37% | vs 2487 |
| Revolution Medicines, Inc RVMD | $172.29 | $88.78 | −48% | vs 2487 |
| Celltrion, Inc 068270 | 214,000 KRW | 74,945 KRW | −65% | vs 2487 |
| Royalty Pharma plc RPRX | $69.31 | $19.01 | −73% | vs 2487 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Cutia Therapeutics (2487) overvalued or undervalued?
What is the fair value of 2487?
What is the quality score of 2487?
What is the price target for Cutia Therapeutics (2487)?
What is the Cutia Therapeutics stock forecast for 2026?
What is the revenue of Cutia Therapeutics (2487)?
What is the intrinsic value of Cutia Therapeutics (2487)?
Is Cutia Therapeutics stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 2487?
How much is Cutia Therapeutics worth?
What do the bullish and bearish scenarios say about 2487?
How solid is the balance sheet of Cutia Therapeutics (2487)?
How far is 2487 from its 52-week high?
Which stocks are comparable to Cutia Therapeutics?
Is Cutia Therapeutics stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Cutia Therapeutics (2487)?
What should I pay attention to with Cutia Therapeutics right now?
Key figures of Cutia Therapeutics
How large is the market capitalisation of Cutia Therapeutics (2487)?
What is the P/S ratio of Cutia Therapeutics (2487)?
What is the net margin of Cutia Therapeutics (2487)?
What is the return on equity of Cutia Therapeutics (2487)?
What is the EBIT return on assets of Cutia Therapeutics (2487)?
What is the operating margin of Cutia Therapeutics (2487)?
How fast is revenue growing at Cutia Therapeutics (2487)?
How much free cash flow does Cutia Therapeutics (2487) generate?
How much net debt does Cutia Therapeutics (2487) carry?
Watch Cutia Therapeutics in the live analysis
One click puts Cutia Therapeutics on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.